Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2206 to 2220 of 7707 results

  1. Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]

    In development [GID-TA11117] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Ferric maltol for treating iron deficiency anaemia in children and adolescents aged 1 month to 17 years TS ID 11994

      Status ...

    Technology appraisal guidance
    Topic selection

  3. Elinzanetant for treating vasomotor symptoms associated with menopause [ID6359]

    Awaiting development [GID-TA11428] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over ID6284

    In development [GID-TA11334] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071]

    In development [GID-TA11058] Expected publication date: 21 May 2025

    Technology appraisal guidance
    In development

  6. Osteoporosis

    Awaiting development [GID-QS10188] Expected publication date: TBC

    Quality standard
    Awaiting development

  7. Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317

    In development [GID-TA11340] Expected publication date: 21 May 2025

    Technology appraisal guidance
    In development

  8. Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]

    Awaiting development [GID-TA11336] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines ID6356

    Awaiting development [GID-TA11416] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Ranibizumab port delivery system for treating diabetic macular oedema ID6137

    Awaiting development [GID-TA11065] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA963) [ID6426]

    Awaiting development [GID-TA11536] Expected publication date: 21 May 2025

    Technology appraisal guidance
    Awaiting development

  12. Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310]

    In development [GID-TA11504] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]

    Awaiting development [GID-TA10757] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Artificial intelligence (AI)-derived software to help clinical decision making in stroke (DG57)

    Evidence-based recommendations on artificial intelligence-derived software to help clinical decision making in stroke

    Diagnostics guidance
    Last updated
    2 May 2024
    View recommendations

    Sections for DG57

  15. Cefepime–enmetazobactam for treating hospital-acquired pneumonia, including ventilator-associated pneumonia TS ID 12035

      Status ...

    Technology appraisal guidance
    Topic selection